EGFR and colorectal carcinoma: Notably, cetuximab and panitumumab have not significantly affected survival rates in CRC with KRAS exon 2 activating mutations, indicating that the efficacy of EGFR inhibitors is primarily observed in KRAS wild‐type CRC [203].